{"id":"NCT02091375","sponsor":"Jazz Pharmaceuticals","briefTitle":"Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)","officialTitle":"A Double Blind, Placebo Controlled Two-part Study to Investigate the Dose-ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-03-30","primaryCompletion":"2015-11-26","completion":"2015-11-26","firstPosted":"2014-03-19","resultsPosted":"2018-07-20","lastUpdate":"2022-09-28"},"enrollment":120,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Epilepsy","Dravet Syndrome"],"interventions":[{"type":"DRUG","name":"GWP42003-P 20 mg/kg/day Dose","otherNames":["Cannabidiol","Epidiolex"]},{"type":"DRUG","name":"Placebo control","otherNames":["Placebo"]}],"arms":[{"label":"GWP42003-P 20 mg/kg/day Dose","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"To investigate the potential antiepileptic effects of cannabidiol (GWP42003-P) in children and young adults with Dravet syndrome.","primaryOutcome":{"measure":"Percentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period","timeFrame":"Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)","effectByArm":[{"arm":"GWP42003-P 20 mg/kg/Day Dose","deltaMin":-38.94,"sd":null},{"arm":"Placebo","deltaMin":-13.29,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0123"}]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":7},"locations":{"siteCount":22,"countries":["United States","France","Poland","United Kingdom"]},"refs":{"pmids":["28538134","34265088"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":61},"commonTop":["Diarrhoea","Somnolence","Decreased appetite","Pyrexia","Fatigue"]}}